Bristol-Myers Squibb Co. (BMY) News Headlines

▮ More

Date

Headline

7/28/2021 7:43:00 AM Bristol-Myers Squibb Co. Q2 adjusted earnings Beat Estimates

7/28/2021 7:41:09 AM Bristol-Myers Squibb Reaffirms FY21 Adj. EPS Outlook - Quick Facts

7/28/2021 7:09:08 AM Bristol-Myers Q2 EPS $0.47 And Non-GAAP EPS $1.93

7/28/2021 7:00:03 AM Bristol-Myers Squibb Q2 21 Earnings Conference Call At 8:00 AM ET

7/27/2021 7:57:04 AM BridgeBio, Bristol Myers To Study BBP-398 In Combination With OPDIVO In Advanced Solid Tumors

7/16/2021 7:56:15 AM Bristol Myer : Phase 3 Trial On Head & Neck Cancer Fails To Meet Primary Endpoints

7/16/2021 7:05:25 AM Bristol Myers Squibb Provides Update On CheckMate -651 Trial

6/29/2021 7:38:19 AM EC Approves Bristol Myers' Opdivo - Yervoy For Mismatch Repair Deficient Treatment

6/25/2021 7:47:23 AM Bristol Myers Gets Positive CHMP Opinion For Abecma On Relapsed & Refractory Multiple Myeloma

6/25/2021 7:40:07 AM Bristol Myers Gets Positive CHMP Opinion For Opdivo To Treat Esophageal Cancer

6/24/2021 8:59:21 AM Prothena To Receive $80 Mln From Bristol Myers For US License To PRX005 On Alzheimer's Disease

6/17/2021 11:15:35 PM Bristol Myers Enters Into Collaboration For Eisai's MORAb-202 Antibody Drug Conjugate

6/14/2021 8:34:07 AM Exelixis, Bristol Myers To Evaluate XL092-Immuno-oncology Therapies In Advanced Solid Tumors

6/14/2021 8:13:47 AM Exelixis Announces Clinical Trial Collaboration And Supply Agreement With Bristol Myers Squibb For STELLAR-002

6/11/2021 5:43:09 AM BMY, Acceleron Announce New Data From Reblozyl Phase 2 Trial For Adults With NTD Beta Thalassemia

6/10/2021 7:59:24 AM BMY Reports Positive Results From Phase 3 Breyanzi Trial In Second-line Relapsed Or Refractory LBCL

6/2/2021 8:21:09 AM Health Canada Approves Bristol Myers' Opdivo Plus Yervoy To Treat Mesothelioma - Quick Facts

6/2/2021 7:24:03 AM EC Approves Bristol Myers' Opdivo Plus Yervoy To Treat Mesothelioma - Quick Facts

6/2/2021 7:09:21 AM Bristol Myers Squibb To Present Data From 28 Company-sponsored And Investigator-sponsored Studies

5/25/2021 8:33:06 AM Xencor, Bristol Myers Ink License Deal To Use Xtend XmAb Technology To Treat COVID-19 - Quick Facts